This study evaluated the effects of resveratrol supplementation on inflammatory biomarkers and quality of life in patients with active ulcerative colitis. Researchers conducted a randomized, double-blind, placebo-controlled study of 50 patients with mild to moderate ulcerative colitis, who were divided into a treatment group that received 500 mg of resveratrol daily or a placebo control group. The treatment group demonstrated significant reductions in inflammatory markers like TNF-α and hs-CRP compared to baseline and the placebo group. Quality of life scores also improved significantly in the treatment group. However, the study had limitations like a small sample size from a single hospital. More research with larger, more diverse samples is still needed to substantiate the results.

1. DoesResveratrol produce anti-InflammatoryeffectsinpatientswithUlcerativeColitis?
Because Ulcerative Colitis(UC) isan inflammatoryboweldisease, the focus of itstreatmentistoreduce
pro-inflammatoryand/orincrease anti-inflammatorymolecules. Mostpatientsuse drugtherapiessuch
as aminosalicylates,glucocorticosteroids,immunemodulators,antibioticsandanti-TNFdrugsas
treatment.However,these drugs come with manyadverse sideeffects,indicatingthe needforabetter
therapy.
Due to its role inmodulatingoxidation,resveratrol,whichisanatural phenoliccompoundcommonly
foundingrapes,berriesandpeanuts,isone potential candidate forpreventingandtreating
inflammationinIBDs.Currently,there are noexistingstudies thatevaluatethe effectsof resveratrol in
patientswithUC. Thus,the aim of thisstudywas to assessthe effectsof resveratrol supplementation as
an anti-inflammatoryand antioxidantagentoninflammatorybiomarkers andqualityof life inpatients
withactive UC.
The researchersdesigneda randomized,double-blind,placebo-controlledstudyinvolvingasample size
of 50 patients withactive mildtomoderate UC. These patientswere selectedaftertheirreferral tothe
GastroenterologyClinicof ImamKhomeini Hospital, inTehran,Iran.Inclusioncriteriaconsistedof:their
tendencytotake part inthe study,mildtomoderate active UC(as notedpreviously),malesandfemales
≥18 yearsof age andBMI of 18.5-30 kg/m2
.Exclusioncriteriaconsistedof:drugtype anddosage change
withinlastmonth,evidentafflictionwithotherintestinal diseasesordisorders,cancer,inflammatory
and infectiousdiseases,pregnancyorlactation,historyof takingsupplementssuchasMVIs,omega-3s,
polyphenolicsandantioxidants,takinganti-coagulationdrugs(heparinandwarfarinorNSAIDs),
antihistaminesandcalciumchannel antagonistssuchasnifedipinewithin the pastmonth, disease
relapse requiringhospitalizationandchangingthe type anddosage of the drugs duringthe intervention.
Afterscreening,50eligibleparticipantswere enrolledinthe studyandevenlydividedintoa treatment
group(n=25) or control group(n=25). The treatmentgroupreceiveda500-mg resveratrol supplement
daily for6 weeks,while the control groupreceivedaplacebocapsule dailyforthe same periodof time.
Seruminflammatorymarkers, NF-κBactivityinperipheral bloodmononuclearcells(PBMC) andquality
of life, viavalidatedquestionnaires, were assessedatbaselineandatthe endof the study.
Resultsindicatedthat resveratrolsupplementationledtoa significantreductioninplasmalevelsof TNF-
α (19.70 ± 12.80 to 17.20 ± 10.09 pg/mL) and hs-CRP(4764.25 ± 2260.48 to 2584.50 ± 1792.80 ng/mL) as
well asdecreased activityof NF-κBinPBMCs(0.19 ± 0.05 to 0.10 ± 0.04 OD) (p < 0.001). In contrast, no
significantchangesinthese factorswere found inthe placebogroup.Moreover,the score forthe IBD
questionnaire-9increased,while the clinical colitisactivityindexscore decreasedsignificantlyinthe
resveratrol group(32.72 ± 7.52 to 47.64 ± 8.59) (p < 0.001) andwhen comparedto the placebogroup
(35.54 ± 9.50 to 41.08 ± 6.59) (p < 0.001).
In conclusion,thisstudysuggeststhat500mg resveratrol supplementationforsix weekscanimprove
qualityof life andreduce some inflammationinpatientswithmildtomoderate UC.Some limitationsof
the studyinclude aconvenience sample of patientsfromthe Gastroenterology Clinicof ImamKhomeini
Hospital,whichisa veryspecificpopulation,ashortstudyduration(1 ½ months) andrelativelysmall
sample size (25people ineachgroupis nothighlypowered).Withthese limitations,especiallysucha
specificsample population,itisdifficulttogeneralizethese resultstothe largerpopulation.WhileIdo
see a great potential forthe use of resveratrol supplementationintreatinginflammationinIBDs,Ithink
more researchisneeded ona largersample size tosubstantiate the resultsof the study.Fornow,Ido

2. not see the harmin recommendingIBDpatientssimplyobtaintheirresveratrol fromwhole foodslike
grapes,berriesandpeanuts,whichmayhave more beneficialsynergisticeffectsanyway.
Reference:
1. SamsamikorM, Daryani NE, Asl PR,HekmatdoostA.Anti-inflammatoryeffectsof resveratrol in
patientswithulcerative colitis:A randomized,double-blind,placebo-controlledpilotstudy. Archivesof
Medical Research.May 19, 2015. doi:10.1016/j.arcmed.2015.05.005.
; No volume(Noissue):Nopages…werelisted.